National, Multicentre, Non-interventional, Prospective and Retrospective Study in Adolescent Patients With Severe Uncontrolled Asthma Starting Treatment With Dupilumab (Dupixent)
Latest Information Update: 17 Jun 2024
At a glance
- Drugs Dupilumab (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Acronyms PEDIASTHMA
- Sponsors Sanofi
- 13 Jun 2024 Planned End Date changed from 15 Dec 2025 to 28 Apr 2025.
- 13 Jun 2024 Status changed from recruiting to active, no longer recruiting.
- 24 Aug 2023 Planned End Date changed from 2 Nov 2023 to 15 Dec 2025.